The pharmacoeconomics of neuromuscular blocking drugs

Anesthesia and Analgesia

Volumn 90, Issue 5 SUPPL., 2000, Pages

  Chiu, Jen W ^a   White, Paul F ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISATRACURIUM; MIVACURIUM; NEUROMUSCULAR BLOCKING AGENT; ROCURONIUM;

AMBULATORY SURGERY; CAPITATION FEE; DRUG COST; DRUG SAFETY; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH CARE UTILIZATION; HEALTH ECONOMICS; MANAGED CARE; NEUROMUSCULAR BLOCKING; PATIENT CARE; PRIORITY JOURNAL; QUALITY OF LIFE; REIMBURSEMENT; REVIEW;

EID: 0034101435     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000539-200005001-00005     Document Type: Review

References (40)

1. Watcha MF, White PF. Is the introduction of new anesthetic drugs and techniques economically justified? Curr Opin Anaesth 1997;10:158-62.
2. Watcha MF, White PF. Economics of anesthetic practice. Anesthesiology 1997;86:1170-96.
3. Kapur PA. Pharmacy acquisition costs: responsible choices versus overutilization of costly pharmaceuticals. Anesth Analg 1994;78:617-8.
4. Orkin FK. Moving toward value based anesthesia care. J Clin Anesth 1993;5:91-8.
5. Macario A, Vitez TS, Dunn B, McDonald T. Where are the costs in perioperative care: analysis of hospital costs and charges for inpatient surgical care. Anesthesiology 1995;83:1138-44.
6. Edge G, Morgan M. Anaesthesia: value for money. Anaesthesia 1996;51:105-6
7. Becker KE Jr, Carrithers J. Practical methods of cost containment in anesthesia and surgery. J Clin Anesth 1994;6:388-99.
8. Szocik JF, Learned DW. Impact of a cost containment program on the use of volatile anesthetics and neuromuscular blocking drugs. J Clin Anesth 1994;6:378-82.
9. DeMonaco HJ, Shah AS. Economic considerations in the use of neuromuscular blocking drugs. J Clin Anesth 1994;6:383-7.
10. Johnstone RE, Jozefczyk KG. Costs of anesthetic drugs: experiences with a cost education program. Anesth Analg 1994;78: 766-71.
11. Puura AE, Rorarius MGF, Manninen P, et al. The costs of intense neuromuscular blockade for anesthesia during endolaryngeal procedures due to waiting time. Anesth Analg 1999;88:1335-9.
12. Doubilet P, Weinstein MC, McNeil BJ. Use and misuse of the term "cost effective" in medicine. N Engl J Med 1986;314:253-6.
13. Vitez TS. Principles of cost analysis. J Clin Anesth 1994;6: 357-63.
14. Johnstone RE, Valenzuela RC, Sullivan D. Monitoring pharmaceutical sales activity in an academic anesthesiology department. J Clin Anesth 1995;7:544-8.
15. Caldwell JE. The problem with long-acting muscle relaxants? They cost more! Anesth Analg 1997;85:476-82.
16. Freund PR, Bowdle TA, Posner KL, et al. Cost-effective reduction of neuromuscular blocking drug expenditures. Anesthesiology 1997;87:1044-9.
17. Harper MCG, Hessel IE, Shadick D. Effect of prescribing guidelines on the use of neuromuscular blocking agents. Am J Health Syst Pharm 1995;52:1900-4.
18. Kirsch MA, Carrithers JA, Hagan RH, Borra HM. Effects of a low-cost protocol on outcome and cost in a group practice setting. J Clin Anesth 1998;10:416-24.
19. Horrow JC, Rozenberg H. Price stickers do not alter drug usage. Can J Anaesth 1994;41:1047-52.
20. Greco PJ, Eisenberg JM. Changing physician practices. N Engl J Med 1993;329:1271-3.
21. Woehlck HJ, Brown B. Synergistic combinations of muscle relaxants may reduce costs, [letter] Anesth Analg 1996;82:888.
22. Lubarski DA, Glass PSA, Ginsberg B, et al. The successful implementation of pharmaceutical practice guidelines: analysis of associated outcomes and cost savings. Anesthesiology 1997; 86:1145-60.
23. Bevan DR, Smith CE, Donati F. Postoperative neuromuscular blockade: a comparison between atracurium, vecuronium and pancuronium. Anesthesiology 1988;69:272-6.
24. Eriksson LI, Sundman E, Olsson R, et al. Functional assessment of the pharynx at rest and during swallowing in partially paralyzed humans. Anesthesiology 1997;87:1035-43.
25. Berg H, Viby-Mogensen J, Roed J, et al. Residual neuromuscular blockade is a risk factor for postoperative pulmonary complications. Acta Anesthesiol Scand 1997;41:1095-103.
26. Ballantyne JC, Chang Y. The impact of choice of muscle relaxants on postoperative recovery time: a retrospective study. Anesth Analg 1997;85:476-82.
27. Dexter F, Tinker JH. Analysis of strategies to decrease postanesthetic care unit costs. Anesthesiology 1995;82:94-101.
28. Apfelbaum JL. Bypassing PACU: a cost effective measure. Can J Anaesth 1998;45:R91-2.
29. Sladen RN. Neuromuscular blocking agents in the intensive care unit: a two-edged sword. Crit Care Med 1995;23:423-6.
30. Tobias JD, Lynch A, McDuffee A, Garrett JS. Pancuronium infusion for neuromuscular blockade in children in the pediatric intensive care unit. Anesth Analg 1995;81:13-6.
31. Murray MJ, Courson DB, Scuderi PE, et al. Double-blind, randomized, multicenter study of doxacurium versus pancuronium in intensive care unit patients who require neuromuscular blocking agents. Crit Care Med 1995;23:450-8.
32. Wierda JM, van den Broek L, Proost JH, et al. Time course of activity and endotracheal intubating conditions of Org 9487, a new short-acting steroidal muscle relaxant: a comparison with succinylcholine. Anesth Analg, 1993;77:579-84.
33. Debaene B, Lieutaud T, Billard V, Meistelman C. ORG 9487 neuromuscular blockade at the adductor pollicis and the laryngeal adductor muscles in humans. Anesthesiology 1997;86: 1300-5.
34. Tang J, Joshi GP, White PF. Comparison of rocuronium and mivacurium to succiny1choline during outpatient laparoscopic surgery. Anesth Analg 1996;82:994-8.
35. Meistelman C, Plaud B, Donati F. Rocuronium (ORG 9486) neuromuscular blockade at the adductor muscles of the larynx and adductor pollicis in humans. Can J Anaesth 1992;39:665-9.
36. Kahwaji R, Bevan DR, Bikhazi G, et al. Dose ranging study in younger adults and elderly patients of ORG 9487, a new, rapid onset, short-duration muscle relaxant. Anesth Analg 1997;84: 1011-8.
37. McCourt KC, Mirakhur RK, Lowry DW, et al. Spontaneous or neostigmine-induced recovery after maintenance of neuromuscular block with Org 9487 (rapacuronium) following an initial dose of Org 9487. Br J Anaesth 1999;82:755-6.
38. Schiere S, Proost JH, Schuringa M, Wierda JM. Pharmacokinetics and pharmacokinetic-dynamic relationship between rapacuronium (Org 9487) and its 3-desacetyl metabolite (Org 9488). Anesth Analg 1999;88:640-7.
39. Enlund M, Kobosko P, Thodin A. A cost-benefit evaluation of using propofol and alfentanil for a short gynaecological procedure. Acta Anaesth Scand 1996;40:416-20.
40. Kapur PA. Cost containment: at what expense? Anesth Analg 1995;81:897-9.